ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms
Future Oncology · 2023
DOI: 10.2217/fon-2022-0512 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Future Oncology, 2023. Verfasst von Francesco Mannelli und 9 weiteren Autor:innen. Beteiligte Einrichtung: SOD Ematologia, AOU Careggi, Firenze, Italy. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Myeloproliferative Disorders. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Associazione Italiana per la Ricerca sul Cancro.
Abstract (Originalsprache)
The management of patients with acute myeloid leukemia (blast phase) secondary to myeloproliferative neoplasms (MPNs) is extremely challenging and the outcome dismal, with a median overall survival of about 3-6 months. Effective therapeutic approaches are lacking, especially when intensive strategies followed by allogeneic transplantation are not feasible. The combination of venetoclax and hypomethylating agents has recently been established as standard for newly diagnosed, unfit patients with de novo acute myeloid leukemia, but the application of this therapeutic modality has not been tested prospectively in the specific context of blast-phase MPNs. ENABLE is an open, phase II clinical trial aimed at verifying the efficacy and safety of the combination of venetoclax and decitabine in patients with post-MPN blast phase. The evolution into a blast phase represents a dramatic and often fatal event in the disease course of patients affected by myeloproliferative neoplasms. Aside from a minority of patients who can be offered an allogeneic transplant, the median survival from disease evolution is about 3–6 months. There is a serious unmet need for clinical trials with innovative approaches for this category of patients. In the ENABLE clinical trial, we aim to verify the efficacy and safety of the combination of venetoclax (a BCL2 inhibitor) and decitabine (a hypomethylating agent) in this disease subset, characterized by a complex dynamic of clonal evolution and a particularly unfavorable prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- SOD Ematologia, AOU Careggi, Firenze, Italy.
- Centro Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, 50134, Firenze, Italy.
- Fondazione GIMEMA, 00182, Roma, Italy.
- UO di Ematologia e Trapianto di Cellule Staminali Emopoietiche, AOU 'Federico II', 80131, Napoli, Italy.
- Ematologia, Dipartimento di Biomedicina e Prevenzione, Università di Tor Vergata, 00133, Roma, Italy.
- Fondazione Policlinico Tor Vergata, 00133, Roma, Italy.
ORCID-Profile: Francesco Mannelli
Förderung
- Associazione Italiana per la Ricerca sul Cancro
Zitieren
APA
Mannelli, F., Guglielmelli, P., Fazi, P., Crea, E., Piciocchi, A., Vignetti, M., Amadori, S., Pane, F., Venditti, A., & Vannucchi, A. M. (2023). ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms. Future Oncology. https://doi.org/10.2217/fon-2022-0512
Vancouver
Mannelli F, Guglielmelli P, Fazi P, Crea E, Piciocchi A, Vignetti M, et al. ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms. Future Oncology. 2023. doi:10.2217/fon-2022-0512
BibTeX
@article{Mannelli2023,
author = {Mannelli, Francesco and Guglielmelli, Paola and Fazi, Paola and Crea, Enrico and Piciocchi, Alfonso and Vignetti, Marco and Amadori, Sergio and Pane, Fabrizio and Venditti, Adriano and Vannucchi, Alessandro M},
title = {ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms},
journal = {Future Oncology},
year = {2023},
doi = {10.2217/fon-2022-0512}
}
EUVIMED